ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 120

Evaluation of Joint Involvement in Patients Suffering From Early Polymyalgia Rheumatica Using High Resolution Ultrasound

Sandra Balser1, Emmanuelle LeBras1, Boris P. Ehrenstein2, Martina Müller3, Martin Fleck2 and Wolfgang Hartung2, 1Rheumatology & Clinical Immunology, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, 2Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, 3Clinic for Internal Medicine I, University Clinic Regensburg, Regensburg

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Polymyalgia rheumatica and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The new EULAR/ACR 2012 classification criteria for polymyalgia rheumatica (PMR) are the first classification criteria that contain musculoskeletal ultrasound (MUS) in an additional algorithm resulting in an increased specificity. Therefore, the joint involvement has been investigated by MUS in a cohort of recent onset PMR patients analyzing the distribution of the novel ultrasound criteria. 

Methods:

All patients of our tertiary rheumatology center with newly diagnosed PMR between 01/2011 and 06/2012 were included in this retrospective study. MUS has been performed in all patients with suspected PMR. The final diagnosis of PMR was established by a rheumatologist according to physical examination, laboratory analysis, MUS, and after excluding other conditions mimicking PMR. 

Results:

In 35 patients the diagnosis of PMR was established. Pathological MUS findings of shoulder or hip joints were present in 80.0 % of these patients. Biceps tenosynovitis, subdeltoid bursitis or glenohumeral synovitis of at least one shoulder were observed in 74.3% patients. Of those patients with pathological MUS findings of the shoulder, 92.3 % had a biceps tenosynovitis of at least one shoulder, 80.8 % presented with bilateral biceps tenosynovitis, whereas only 46.2 % had a subdeltoid bursitis and 34.6 % a glenohumeral synovitis of at least one shoulder. Synovitis or trochanteric bursitis of at least 1 hip could be detected in 25.7 % of all PMR patients. 66.7 % of the patients with hip affection in MUS presented with pathological MUS findings of both hips and both shoulders (Tab. 1).

 Conclusion:

The most common pathological ultrasound finding in patients with PMR was a (bilateral) biceps tenosynovitis. Pathological ultrasound findings of the hips were less frequent, but in two thirds of these patients combined with pathological findings of both hips and both shoulders.

Table 1:MUS findings in PMR patients.

 

PMR-Patients (n = 35)

At least 1 shoulder with biceps tenosynovitis, subdeltoid bursitis or glenohumeral synovitis

26 (74.3 %)

Both shoulders with biceps tenosynovitis, subdeltoid bursitis or glenohumeral synovitis

24 (68.6 %)

At least 1 shoulder with biceps tenosynovitis or subdeltoid bursitis

26 (74.3 %)

Both shoulders with biceps tenosynovitis or subdeltoid bursitis

22 (62.9 %)

At least 1 shoulder with biceps tenosynovitis

24 (68.6 %)

Both shoulders with biceps tenosynovitis

21 (60.0 %)

At least 1 hip with synovitis or trochanteric bursitis

9 (25.7 %)

Both hips with synovitis or trochanteric bursitis

7 (20.0 %)

Patients with no pathological finding as above

7 (20.0 %)

At least 1 shoulder and 1 hip with findings as above

7 (20.0 %)

Both shoulders and both hips with findings as above

6 (17.1 %)


Disclosure:

S. Balser,
None;

E. LeBras,
None;

B. P. Ehrenstein,

Abbott Immunology Pharmaceuticals,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5;

M. Müller,
None;

M. Fleck,

Abbott Immunology Pharmaceuticals,

5,

Roche Pharmaceuticals,

5,

Pfizer Inc,

5;

W. Hartung,

Abbott Immunology Pharmaceuticals,

5,

Pfizer Inc,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-joint-involvement-in-patients-suffering-from-early-polymyalgia-rheumatica-using-high-resolution-ultrasound/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology